Prostate Cancer - Results from #1440

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer. January 24, 2024

Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer. January 24, 2024

Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood. January 24, 2024

Functional Outcomes After Localized Prostate Cancer Treatment January 23, 2024

Long-Term Follow up Pinpoints Side Effects of Treatments for Prostate Cancer Patients January 23, 2024

The effect of limited english proficiency on prostate-specific antigen screening in American men. January 23, 2024

Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET. January 23, 2024

The future of patient-derived xenografts in prostate cancer research. January 23, 2024

Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts. January 23, 2024

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review. January 23, 2024

Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients. January 23, 2024

Oncologic Outcome of the Extent of Pelvic Lymph Node Dissection During Radical Prostatectomy: A Systematic Review, Meta-analysis, and Network Analysis. January 23, 2024

The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. January 22, 2024

Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. January 22, 2024

Palliative urologic surgery for metastatic prostate cancer: what needs to be considered in the future?. January 22, 2024

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2. January 22, 2024

The impact of transportation mode, socioeconomic deprivation and rurality on travel times to radiotherapy and surgical services for patients with prostate cancer: a national population-based evaluation. January 22, 2024

Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. January 22, 2024

Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients. January 22, 2024

Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis. January 22, 2024

Page 73 of 1435